TITRE Le projet : un protocole pour chaque enfant : Registre, Éligibilité et Étude de la Biologie et des Résultats.
PROTOCOLE ID COG-APEC14B1
CLINICAL TRIAL.gov ID NCT02402244
TYPE(S) DE CANCER Pédiatrique divers
PHASE
TYPE D'ÉTUDE
INSTITUTION CENTRE HOSPITALIER UNIVERSITAIRE SAINTE-JUSTINE
3175 Chemin de la Côte Sainte-Catherine
(514) 345-4931
VILLE Montréal
INVESTIGATEUR(RICE) PRINCIPAL(E) Yvan Samson
COORDONATEUR(RICE) Linda Hershon
linda.hershon@recherche-ste-justine.qc.ca
514-345-4931 poste 5899
STATUT  Actif en recrutement
CRITÈRES D'ÉLIGIBILITÉ (EN)
  • Enrollment can occur at any time after disease presentation including at time of disease progression or recurrence; for patients who are to be enrolled on COG therapeutic studies, enrollment on APEC14B1 must occur prior to enrollment onto the therapeutic trial
  • Patients with a known or suspected neoplasm that occurs in the pediatric, adolescent or young adult populations are eligible for enrollment as follows:

  • All cancer cases with an International Classification of Diseases for Oncology (ICD-O) histologic behavior code of two "2" (carcinoma in situ) or three "3" (malignant)
  • All neoplastic lesions of the central nervous system regardless of behavior, i.e., benign, borderline or malignant
  • Other benign/borderline conditions including:

  • Mesoblastic nephroma
  • Teratomas
  • Myeloproliferative diseases including transient myeloproliferative disease
  • Langerhan cell histiocytosis
  • Lymphoproliferative diseases
  • Subjects must be =< 25 years of age at time of original diagnosis, except for patients who are being screened specifically for eligibility onto a COG (or COG participating National Clinical Trials Network (NCTN) ) therapeutic study, for whom there is a higher upper age limit
  • All patients or their parents or legally authorized representatives must sign a written informed consent; parents will be asked to sign a separate consent for their own biospecimen submission
CRITÈRES D'EXCLUSION (EN)